 |
 |
|
|
| |
Graffinity - fragment based drug discovery
 Graffinity is the premier partner for fragment based drug discovery and lead development of small molecule pharmaceuticals. Graffinity has built a unique approach which includes chemical microarrays, fragment screening, SPR label-free imaging of protein-ligand interactions, computational chemistry and lead discovery. The technology platform offers a new drug discovery paradigm for the rapid conversion of genomic information into novel, high quality leads and drug candidates.
Graffinity applies this technology in established high-profile collaborations with leading Pharma and Biotech companies.
|
|
|
|
|
|
| |
 |
|
Press Releases:
|
 June 3, 2008:
Graffinity and Rigel enter into drug discovery research alliance
 read more ...
|
|
November 29, 2007:
Graffinity announces multitarget drug discovery research collaboration with Pfizer
read more ...
|
|
February 26, 2007:
Graffinity and Amgen enter into drug discovery research agreement
read more ... |
|
|
|
|
|
|
|
|
|
|
| |
 |
|
Our next meetings:
|
June 10 - 11, 2008:
SBS Symposium - Europe 2008, Dresden, Germany
Exhibition
read more ... |
|
April 28-30, 2008:
Drug Discovery Chemistry: Fragment-based Lead Discovery Conference 2008, La Jolla, California
Exhibition
read more ... |
|
April 14-16, 2008:
Barcelona BioMed Conference: Targeting and Tinkering with Interaction Networks, Barcelona, Spain
Presantation
read more ... |
|
April 8th and 9th, 2008:
First International Workshop on Label-free Biosensing
(LFB 2008), The University of Twente, Enschede, The Netherlands
Presentation and Exhibition
read more ... |
|
March 2-5, 2008:
Annual Meeting on Frontiers in Medicinal Chemistry, Regensburg, Germany
Poster
read more ... |
|
February 19-20, 2008:
Screening Europe 2008, Stockholm, Sweden
Presentation
read more ... |
|
February 18-20, 2008:
Fragment-based Lead Discovery Conference 2008, San Diego, USA
Exhibition
read more ... |
|
Complete list of meetings
Click here for the complete list. |
|
|
|
|
|
|
